Fig. 5. Dose-dependent efficacy and toxicity of subcutaneously administered DRP-104 in EL4 tumor-bearing C57BL/6/CES1^−/− mice.

(A) DRP-104 administration (0.1, 0.3, and 1 mg/kg DON equivalent delivered subcutaneously 5 days per week) resulted in a dose-dependent reduction in tumor growth with complete tumor regression at the higher two doses. (B) Minimal effects on body weight were observed at all doses. (C) Subcutaneous administration of DRP-104 had no adverse effect on GI histopathology at the lower doses; at the highest dose, mild lymphocytic infiltration (indicated by red arrows) was observed. Scale bars, 100 μm. Original magnification, ×20.